secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001437749-23-005679
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen gets 180-day Nasdaq extension to Sept 5, 2023 to regain $1 bid price compliance
--------------------------------------------------------------------------------

- Company failed to meet $1.00 minimum bid price by March 6, 2023 deadline.
- Nasdaq granted extension until September 5, 2023 to cure deficiency.
- If not compliant by Sept 5, Nasdaq will initiate delisting; company may appeal.
- No effect on current listing; trading continues on Nasdaq Capital Market.
- Previously disclosed in September 2022 that bid price had been below $1 for 30 consecutive days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923005679/0001437749-23-005679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923005679/vtgn20230307_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-005679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer